Denosumab delays skeletal-related side effects in breast cancer and bone metastases p

[News]

For patients with breast cancer and bone metastases, denosumab delayed skeletal-related side effects five months longer compared to those on zoledronic acid, according to results presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.

More... (http://www.news-medical.net/news/20101213/Denosumab-delays-skeletal-related-side-effects-in-breast-cancer-and-bone-metastases-patients.aspx)